Abstract
Siemens Medical Solutions is well-known for its medical imaging systems,
including X-ray, computed tomography (CT), magnetic resonance imaging (MRI),
positron emission tomography (PET), mammography, angiography, ultrasound and
molecular imaging (MI) products, as well as related computer-based
workstations, healthcare IT systems, oncology care products and audiology
products such as hearing aids. This report provides a full review of the
company' s activities.
Siemens AG' s medical division, Siemens Medical Solutions, represents over 9%
of its parent company' s total revenue. Headquartered in Erlangen, Germany,
Siemens Medical Solutions is well-known for its medical imaging systems,
including X-ray, computed tomography (CT), magnetic resonance imaging (MRI),
positron emission tomography (PET), mammography, angiography, ultrasound and
molecular imaging (MI) products, as well as related computer-based
workstations, healthcare IT systems, oncology care products and audiology
products such as hearing aids. Siemens also has a share in Drager Medical, a
leader in the market for electromedical systems, including patient monitoring
products and electrophysiological measuring systems.
Having established itself as a leader in in vivo diagnostics, the company has
recently also made the move into the global in vitro diagnostics market,
acquiring Bayer' s diagnostic division in January 2007 and Diagnostic Products
Corporation (DPC) in July 2006. These companies now operate as the new Siemens
Medical Solutions Diagnostics unit, employing over 8,000 people and
headquartered in Tarrytown, New York, and Los Angeles, California, USA.
Siemens Medical Solutions Diagnostics offers products for clinical chemistry,
patient testing, laboratory automation, haematology, molecular diagnostics and
gene analysis. Its products are used to diagnose and treat an array of
illnesses such as adrenal/pituitary dysfunction, allergy, anaemia,
reproductive and thyroid disorders, infectious diseases, kidney ailments,
cardiology, oncology, diabetes and virology.
Siemens now claims to hold the second-leading position in the global
immunodiagnostics market and is number three in the overall in vitro
diagnostics market after Roche and Abbott. DPC and Bayer Diagnostics generated
cumulative sales of EUR 1.8 billion in fiscal 2005, ended 31st December. The
cost for both acquisitions was EUR 5.7 billion.
In its traditional operations, Siemens Medical Solutions claims to be the
global market leader for hearing systems. The company holds a leading or
second position in the markets for diagnostic imaging and healthcare IT
products, along with GE Healthcare and Philips. It also holds the number three
position in the global oncology market after Varian Medical Systems and Elekta.
Siemens is often at the forefront in responding to new trends in the
healthcare industry and has built its operations through internal growth,
strategic alliances and mergers and acquisitions. The recent addition of its
diagnostics business is a good example. In addition, when molecular imaging
was a key new area of expansion, the company consolidated its position in this
growth market by the acquisition of its former partner, CTI Molecular Imaging,
in 2005. CTI was merged with Siemens' existing nuclear medicine activities to
form a new Molecular Imaging division.
A more recent example is Siemens' acquisition of Gesellschaft für
Systemforschung und Dienstleistungen im Gesundheitswesen mbH (GSD), a German
healthcare IT company. By taking over GSD, Siemens aims to strengthen its
position in the healthcare IT sector, especially in Europe. GSD' s healthcare
IT portfolio includes the i.s.h.med and Ambulatory Care Management (ACM)
product lines GSD generated revenue of EUR 25.6 million and employed 168
people in fiscal 2005, ended 31st December.
R&D plays an important role in Siemens Medical Solutions' business and the
company maintains R&D centres in Europe, the US and Asia. Currently, the main
themes are the development of new technologies such as MI and particle
therapy, a cutting-edge technology which many believe will lead to improved
radiation therapy for oncology care. The company also focuses on enhancing
existing technologies such as CT, ultrasound, mammography, ultrasound and MRI.
To complement its internal development, Siemens has many R&D alliances with
companies and academic institutions. The company has recently begun US
clinical trials with the University of California, Los Angeles, under an FDA
investigational new drug application for an imaging biomarker designed to
identify Alzheimer' s disease before the onset of noticeable symptoms. It has
also developed prototype 128-channel MRI system based on its Tim MRI
technology in collaboration with Massachusetts General Hospital and signed a
licensing agreement for SPECT reconstruction and calibration software
developed by the Cleveland Clinic.
Siemens has a strong global presence. The US is the largest single market for
its medical device operations, representing around half of sales, followed by
Europe and a smaller but significant amount in the Asia-Pacific region. The
company' s worldwide business is reflected in its regional organisation. The
headquarters for the diagnostics, oncology care, healthcare IT, services,
ultrasound and MI divisions are located in the US, while the remaining
divisions are headquartered in Germany. The company operates manufacturing
facilities throughout North America and Europe, as well as in China and India.
It also has joint-venture operations in Germany, the US, the UK, China and
Japan.
This company report provides Executive Summary
An overview of the company, including operating activities, at a glance key
events and strategic focus.
Product Portfolio and R&D
The product section of the report focuses on the key aspects of the company' s
portfolio and technology, covering core products, key brands, new products and
analysis of the competition. Sales data, market size and future potential is
included where available.
International Activities
The company' s business activities by geographic region and country.
Appendices
- Financial Indicators
- Key corporate events
- Mergers & acquisitions
- Joint Ventures
- Minority Investments
- Divestitures
- Agreements
- Litigation
View Cart
